Possibilities of Infection and Increase of Intraocular Pressure After Intravitreal Application of Bevacizumab in Treatment of Exudative Form of AMD

The goal is established the frequency increase of intraocular pressure (IOP) andendophthalmitis as well as other complications that may occur after intravitrealapplication of bevacizumab. Subjects and methodology: The study included45 patients and 75 eyes with exudative form of senile degeneration of macula lutea,who were treated in the General Hospital “Prim. Dr. Abdulah Nakas” from 2007.and 2010., the patients being aged between 55 and 75 years. The intraocular pressure(IOP) was measured before the application of bevacizumab, and then after1st, 2nd and 3rd dose, and it was examined by the bio-microscope two days afterthe application of bevacuzimab. Result: The average age of the patients treated bybevacizumab was 71.27 years (71 years, 3 months, and 7 days); 28 patients werefemales and 17 were males. The examination by bio-microscope indicates changesat certain number of patients. After first dose of bevacizumab, there were 9 suffusionsof the bulbar conjuctiva in the application area. After the second dose, therewere 10 of them, while after the third dose of bevacizumab, there were 5 suffusionsand 3 cases of inflammation of the anterior eye segment, anterior uveitis. As for theintraocular pressure, there is no statistically significant difference (p 0.05) for anymeasuring period. Conclusion: Based on the results achieved in the intravitrealapplication of bevacizumab in treatment of senile degeneration of macula lutea, wecan conclude that there is a possibility of infection after intravitreal application ofbevacizumab, but it is minimal when working in a sterile environment. Increasedintraocular pressure is possible, but not necessarily to happened after the intravitrealapplication of the drug.